SALT LAKE CITY, March 8, 2022 /PRNewswire/ — ReddyPort®a medical technology company focused on bringing new non-invasive ventilation (NIV) products to market, today announced that U.S. Patent No. 11,222,648 has been issued by the U.S. Patent Office covering a microphone system , a nebulizer and a positive pressure ventilation (PPV) system. related methods. Microphone and ReddyPort controller in combination with Elbow ReddyPort allows patients to communicate clearly with clinicians and their families during treatment, without NIV mask removal or interruption of therapy (CPAP) or at two levels, thereby reducing known risks for successful NIV therapy. For clinicians and family members, it helps alleviate the frustration of not being able to hear or understand the patient behind the NIV mask, especially during a life-threatening or end-of-life illness. The ReddyPort microphone with built-in speaker uses digital signal processing (DSP) to suppress breath sounds and naturalize the patient’s voice. Currently, no product on the market uses this type of technology.
Patients on NIV often experience physical ailments that can impair well-being during NIV treatment, including dry mouth, phlegm buildup, and an inability to communicate. Clinical studies of NIV treatments conclude that mask intolerance is a major cause of overall NIV failure,¹ leading to increased length of hospital stay and poor outcomes. Removal of an NIV mask during critical treatment, including proper oral care, can lead to collapse of airways and alveoli2 and the potential risk of aerosolization and transmission of bioaerosols to healthcare providers.
“ReddyPort Microphone is an essential device designed to enable patients to communicate with caregivers and family members. Effective verbal communication is essential for compliance with the Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services (DHHS), and Joint Commission on Accreditation of Healthcare Organizations (JCAHO) guidelines to protect a patient’s right to manage their care,” said Tony Lair, CEO of ReddyPort. “This is especially important for patients on NIV when they need to communicate with their caregiver or provide end-of-life care guidelines.”
NIV is the use of respiratory support and is often administered through a face mask where air, with added oxygen, is delivered by positive pressure. This treatment is considered non-invasive because it is delivered with a mask fitted to the face, but without the need for tracheal intubation, and used to wean patients from mechanical ventilation. NIV is the first line of treatment for respiratory insufficiency or failure such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF),3-4 Asthma,5 Pneumonia,6 or Acute Respiratory Distress Syndrome (ARDS).7
The Company has been granted 3 patents and has 13 patents pending.
ReddyPort aims to enable a better care experience for patients on NIV. ReddyPort provides NIV patient solutions to improve satisfaction, reduce risk and cost, enable better workflows and improve quality of care.
For more information please contact: